This is the current revision of this page, as edited by JJMC89 bot III (talk | contribs) at 13:17, 10 July 2023 (Moving Category:4-Morpholinyl compunds to Category:4-Morpholinyl compounds per Misplaced Pages:Categories for discussion/Speedy). The present address (URL) is a permanent link to this version.
Revision as of 13:17, 10 July 2023 by JJMC89 bot III (talk | contribs) (Moving Category:4-Morpholinyl compunds to Category:4-Morpholinyl compounds per Misplaced Pages:Categories for discussion/Speedy)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound Pharmaceutical compoundClinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H19N5O |
Molar mass | 309.373 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Bazinaprine (SR-95,191) is an experimental drug candidate. It is a monoamine oxidase inhibitor (MAOI) which is believed to be useful for the treatment of depression. The drug strongly inhibits type A monoamine oxidase, but only weakly inhibits type B. The effects of the drug are reversible in vivo, but not in vitro. In studies, the chemical has been shown to not interact in vivo with other neurotransmitter or drug receptor sites.
See also
References
- Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K (April 1988). "Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro". Journal of Neurochemistry. 50 (4): 1137–44. doi:10.1111/j.1471-4159.1988.tb10584.x. PMID 3346672. S2CID 12521641.
- Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K (January 1987). "SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition". The Journal of Pharmacology and Experimental Therapeutics. 240 (1): 251–8. PMID 3100771.
Monoamine metabolism modulators | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Non-specific |
| ||||||||||
Phenethylamines (dopamine, epinephrine, norepinephrine) |
| ||||||||||
Tryptamines (serotonin, melatonin) |
| ||||||||||
Histamine |
| ||||||||||
See also: Receptor/signaling modulators • Adrenergics • Dopaminergics • Melatonergics • Serotonergics • Monoamine reuptake inhibitors • Monoamine releasing agents • Monoamine neurotoxins |